BAJAJ BROKING

Notification
No new Notification messages
Ather Energy IPO is Open!
Apply for the Ather Energy IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

3906

524742

CAPLIPOINT

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

CAPLIN POINT LAB LTD. performance

Today’s low

Today’s high

₹ 1799.00 ₹ 1900.00
₹ 1822.40

52 week low

52 week high

₹ 1225.00 ₹ 2641.00
₹ 1822.40

Open Price

₹ 1886.00

Prev. Close

₹ 1884.40

Volume (Shares)

87955.00

Total traded value

₹ 1602.89

Upper Circuit

₹ 2261.20

Lower Circuit

₹ 1507.60

info

CAPLIN POINT LAB LTD. Share Price Update

As of the latest trading session, CAPLIN POINT LAB LTD. share price is currently at ₹ 1806.7, which is down by ₹ -77.70 from its previous closing. Today, the stock has fluctuated between ₹ 1799.00 and ₹ 1900.00. Over the past year, CAPLIN POINT LAB LTD. has achieved a return of 41.04 %. In the last month alone, the return has been -8.13 %. Read More...

CAPLIN POINT LAB LTD. fundamentals


  • Market cap (Cr)

    13,720.39

  • P/E Ratio (TTM)

    44.38

  • Beta

    1.35

  • Book Value / share

    201.93

  • Return on equity

    22.43%

  • EPS (TTM)

    42.48

  • Dividend yield

    0.27%

  • Net profit/quarter (Cr)

    74.71

info icon alternate text
  • Market cap (Cr)

    13,817.98

  • P/E Ratio (TTM)

    44.38

  • Beta

    1.31

  • Book Value / share

    201.93

  • Return on equity

    22.43%

  • EPS (TTM)

    42.48

  • Dividend yield

    0.27%

  • Net profit/quarter (Cr)

    74.71

info icon alternate text

CAPLIN POINT LAB LTD. Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 185.23
Operating Expense 113.89
Net Profit 74.71
Net Profit Margin (%) 40.33
Earnings Per Share (EPS) 9.83
EBITDA 106.22
Effective Tax Rate (%) 25.41
Particulars SEP 2024 (Values in Cr)
Revenue 207.93
Operating Expense 116.28
Net Profit 105.74
Net Profit Margin (%) 50.85
Earnings Per Share (EPS) 13.92
EBITDA 141.17
Effective Tax Rate (%) 21.47
Particulars JUN 2024 (Values in Cr)
Revenue 185.64
Operating Expense 110.46
Net Profit 72.54
Net Profit Margin (%) 39.07
Earnings Per Share (EPS) 9.55
EBITDA 102.88
Effective Tax Rate (%) 24.96
Particulars MAR 2024 (Values in Cr)
Revenue 139.38
Operating Expense 88.64
Net Profit 69.88
Net Profit Margin (%) 50.13
Earnings Per Share (EPS) 9.20
EBITDA 93.85
Effective Tax Rate (%) 19.59
Particulars DEC 2023 (Values in Cr)
Revenue 132.83
Operating Expense 76.30
Net Profit 55.45
Net Profit Margin (%) 41.74
Earnings Per Share (EPS) 7.30
EBITDA 81.22
Effective Tax Rate (%) 25.50
Particulars MAR 2024 (Values in Cr)
Revenue 625.09
Operating Expense 365.19
Net Profit 283.71
Net Profit Margin (%) 45.38
Earnings Per Share (EPS) 37.36
EBITDA 392.92
Effective Tax Rate (%) 22.42
Particulars MAR 2023 (Values in Cr)
Revenue 528.61
Operating Expense 334.46
Net Profit 234.26
Net Profit Margin (%) 44.31
Earnings Per Share (EPS) 30.89
EBITDA 318.91
Effective Tax Rate (%) 20.08
Particulars MAR 2022 (Values in Cr)
Revenue 528.06
Operating Expense 334.29
Net Profit 187.87
Net Profit Margin (%) 35.57
Earnings Per Share (EPS) 24.82
EBITDA 276.17
Effective Tax Rate (%) 24.94
Particulars MAR 2021 (Values in Cr)
Revenue 482.68
Operating Expense 291.36
Net Profit 156.23
Net Profit Margin (%) 32.36
Earnings Per Share (EPS) 20.65
EBITDA 232.54
Effective Tax Rate (%) 25.58
Particulars MAR 2020 (Values in Cr)
Revenue 527.83
Operating Expense 340.66
Net Profit 197.65
Net Profit Margin (%) 37.44
Earnings Per Share (EPS) 26.13
EBITDA 272.96
Effective Tax Rate (%) 21.92
Particulars MAR 2024 (Values in Cr)
Book Value / Share 276.38
ROE % 24.52
ROCE % 26.67
Total Debt to Total Equity 0.00
EBITDA Margin 36.52
Particulars MAR 2023 (Values in Cr)
Book Value / Share 219.22
ROE % 25.72
ROCE % 26.56
Total Debt to Total Equity 0.00
EBITDA Margin 33.89
Particulars MAR 2022 (Values in Cr)
Book Value / Share 167.20
ROE % 27.58
ROCE % 28.38
Total Debt to Total Equity 0.01
EBITDA Margin 34.14
Particulars MAR 2021 (Values in Cr)
Book Value / Share 128.12
ROE % 27.29
ROCE % 28.40
Total Debt to Total Equity 0.03
EBITDA Margin 33.18
Particulars MAR 2020 (Values in Cr)
Book Value / Share 96.68
ROE % 29.26
ROCE % 32.92
Total Debt to Total Equity 0.02
EBITDA Margin 34.92
Particulars MAR 2024 (Values in Cr)
Book Value / Share 183.03
ROE % 22.43
ROCE % 28.84
Total Debt to Total Equity 0.00
EBITDA Margin 62.86
Particulars MAR 2023 (Values in Cr)
Book Value / Share 150.19
ROE % 22.63
ROCE % 28.24
Total Debt to Total Equity 0.00
EBITDA Margin 60.33
Particulars MAR 2022 (Values in Cr)
Book Value / Share 122.78
ROE % 22.24
ROCE % 29.50
Total Debt to Total Equity 0.00
EBITDA Margin 52.30
Particulars MAR 2021 (Values in Cr)
Book Value / Share 100.29
ROE % 23.00
ROCE % 30.68
Total Debt to Total Equity 0.00
EBITDA Margin 48.18
Particulars MAR 2020 (Values in Cr)
Book Value / Share 79.31
ROE % 38.30
ROCE % 48.69
Total Debt to Total Equity 0.00
EBITDA Margin 51.72
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 552.74
Total Assets 2698.12
Total Liabilities 2698.12
Total Equity 2346.83
Share Outstanding 75941746
Price to Book Ratio 7.20
Return on Assets (%) 16.94
Return on Capital (%) 19.47
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 493.48
Total Assets 2191.40
Total Liabilities 2191.40
Total Equity 1907.27
Share Outstanding 75902746
Price to Book Ratio 3.97
Return on Assets (%) 17.16
Return on Capital (%) 19.69
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 462.99
Total Assets 1736.32
Total Liabilities 1736.32
Total Equity 1509.88
Share Outstanding 75788876
Price to Book Ratio 5.54
Return on Assets (%) 17.26
Return on Capital (%) 19.85
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 438.33
Total Assets 1363.61
Total Liabilities 1363.61
Total Equity 1203.37
Share Outstanding 75642750
Price to Book Ratio 4.03
Return on Assets (%) 17.76
Return on Capital (%) 19.85
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 223.42
Total Assets 1125.75
Total Liabilities 1125.75
Total Equity 956.57
Share Outstanding 75642750
Price to Book Ratio 3.56
Return on Assets (%) 19.09
Return on Capital (%) 22.48
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 215.78
Total Assets 1522.31
Total Liabilities 1522.31
Total Equity 1390.15
Share Outstanding 75941746
Price to Book Ratio 7.20
Return on Assets (%) 18.63
Return on Capital (%) 20.41
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 271.38
Total Assets 1303.18
Total Liabilities 1303.18
Total Equity 1139.91
Share Outstanding 75902746
Price to Book Ratio 3.97
Return on Assets (%) 17.97
Return on Capital (%) 20.55
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 316.08
Total Assets 1054.16
Total Liabilities 1054.16
Total Equity 930.65
Share Outstanding 75788876
Price to Book Ratio 5.54
Return on Assets (%) 17.82
Return on Capital (%) 20.19
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 345.49
Total Assets 860.99
Total Liabilities 860.99
Total Equity 758.67
Share Outstanding 75642750
Price to Book Ratio 4.03
Return on Assets (%) 18.14
Return on Capital (%) 20.59
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 58.26
Total Assets 691.32
Total Liabilities 691.32
Total Equity 599.90
Share Outstanding 75642750
Price to Book Ratio 3.56
Return on Assets (%) 28.58
Return on Capital (%) 32.94
Particulars MAR 2024 (Values in Cr)
Net Income 564.43
Cash from Operations 427.39
Cash from Investing -320.04
Cash from Financing -38.07
Net change in Cash -39.72
Free Cash Flow 573.21
Particulars MAR 2023 (Values in Cr)
Net Income 451.35
Cash from Operations 359.37
Cash from Investing -217.58
Cash from Financing -28.17
Net change in Cash 25.62
Free Cash Flow 552.84
Particulars MAR 2022 (Values in Cr)
Net Income 385.82
Cash from Operations 418.23
Cash from Investing -376.77
Cash from Financing -40.68
Net change in Cash -80.72
Free Cash Flow 509.41
Particulars MAR 2021 (Values in Cr)
Net Income 313.62
Cash from Operations 334.75
Cash from Investing -29.44
Cash from Financing -23.98
Net change in Cash 215.19
Free Cash Flow 408.08
Particulars MAR 2020 (Values in Cr)
Net Income 269.46
Cash from Operations 99.44
Cash from Investing -54.50
Cash from Financing 79.76
Net change in Cash 69.93
Free Cash Flow 176.17
Particulars MAR 2024 (Values in Cr)
Net Income 365.74
Cash from Operations 198.10
Cash from Investing -118.94
Cash from Financing -34.26
Net change in Cash -42.19
Free Cash Flow 221.17
Particulars MAR 2023 (Values in Cr)
Net Income 293.15
Cash from Operations 222.14
Cash from Investing -86.67
Cash from Financing -30.42
Net change in Cash 40.01
Free Cash Flow 280.77
Particulars MAR 2022 (Values in Cr)
Net Income 250.31
Cash from Operations 292.95
Cash from Investing -275.93
Cash from Financing -22.76
Net change in Cash -67.72
Free Cash Flow 300.17
Particulars MAR 2021 (Values in Cr)
Net Income 209.94
Cash from Operations 349.54
Cash from Investing -3.71
Cash from Financing -3.47
Net change in Cash 287.46
Free Cash Flow 392.09
Particulars MAR 2020 (Values in Cr)
Net Income 253.12
Cash from Operations 137.35
Cash from Investing -41.05
Cash from Financing -32.91
Net change in Cash 13.03
Free Cash Flow 186.54
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 39.43 21.20 2.15 302.17 34.11 / 77.70
BLISS GVS PHARMA LTD 126.30 16.55 1.31 1330.83 92.25 / 184.95
CIPLA LTD 1551.30 25.11 4.41 125285.64 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 289.65 24.00 2.93 852.47 145.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 39.43 23.75 6.70 302.17 34.11 / 77.70
AMRUTAJAN HEALTH LTD 672.50 39.42 6.52 1944.24 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8961.95 133.66 32.97 22404.88 5000.00 / 9199.00
BLISS GVS PHARMA LTD 126.30 16.40 1.29 1330.83 92.25 / 184.95

CAPLIN POINT LAB LTD. Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
1822.40 -3.29 redarrow
red-green-graph indicator
16 Bearish
0 Bullish
  • 5 Days 1896.90
  • 26 Days 1926.90
  • 10 Days 1904.90
  • 50 Days 1968.00
  • 12 Days 1907.90
  • 100 Days 2003.10
  • 20 Days 1918.50
  • 200 Days 1913.60
1892.37 PIVOT

First Support

1871.63

First Resistance

1908.73

Second Support

1855.27

Second Resistance

1929.47

Third Support

1834.53

Third Resistance

1945.83

RSI

46.32

ADX

24.16

MACD

-18.95

Williams % R

-44.28

Commodity Channel Index (CCI)

-38.05

Date

2025-04-24

Week

56670.00

Same Day

77338.00

Month

47115.00

1 Year

1.36

3 Year

0.85

Over 1 Month

-8.13%

down

Over 1 Year

41.04%

down

Over 3 Months

-12.18%

down

Over 3 Years

34.60%

down

Over 6 Months

1.07%

down

Over 5 Years

40.60%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

CAPLIN POINT LAB LTD. shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
21.7%
Promoter Holdings
70.55%
FII
5.73%
DII
2.0%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
P Vijayalakshmi 1.877879E7 (24.71%) Shareholding of Promoter and Promoter Group
Paarthipan C C 1.4167192E7 (18.64%) Shareholding of Promoter and Promoter Group
Ashok Gorkey Partheeban 9050000.0 (11.91%) Shareholding of Promoter and Promoter Group
Partheeban Vivek Siddarth 9000000.0 (11.84%) Shareholding of Promoter and Promoter Group
May India Property Private Limited 2117000.0 (2.79%) Shareholding of Promoter and Promoter Group
Uti Small Cap Fund 969083.0 (1.27%) Public Shareholding
First Dimension Holdings Private Limited 370000.0 (0.49%) Shareholding of Promoter and Promoter Group
Kiraviz Properties And Consultancy Llp 150000.0 (0.2%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

CAPLIN POINT LAB LTD. corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
14 Sep 2023 2.5 Final 14 Sep 2023 Equity shares
09 Jun 2023 2.0 Interim 09 Jun 2023 Equity shares
21 Sep 2022 2.0 Final 22 Sep 2022 Equity shares
23 May 2022 2.0 Interim 24 May 2022 Equity shares
20 Sep 2021 1.5 Final 21 Sep 2021 Equity shares
18 May 2021 1.5 Interim 19 May 2021 Equity shares
21 Sep 2020 0.4 Final 23 Sep 2020 Equity shares
12 Mar 2020 2.1 Interim 13 Mar 2020 Equity shares
04 Sep 2019 2.2 Final 06 Sep 2019 Equity shares
18 Sep 2018 2.0 Final 20 Sep 2018 Equity shares
07 Sep 2017 1.5 Final 09 Sep 2017 Equity shares
01 Sep 2016 3.5 Final 03 Sep 2016 Equity shares
15 Feb 2016 2.5 Interim 16 Feb 2016 Equity shares
29 Oct 2015 5.0 Final 31 Oct 2015 Equity shares
11 Dec 2014 4.0 Final 13 Dec 2014 Equity shares
19 Dec 2013 2.5 Final 21 Dec 2013 Equity shares
11 Dec 2012 2.0 Final 13 Dec 2012 Equity shares
12 Dec 2011 1.5 Final 24 Dec 2011 Equity shares
09 Dec 2010 1.0 Final 22 Dec 2010 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
19 Oct 2016 10.0 2.0 20 Oct 2016
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
31 May 2024 2.5 Interim 31 May 2024 Equity shares
14 Sep 2023 2.5 Final 14 Sep 2023 Equity shares
09 Jun 2023 2.0 Interim 09 Jun 2023 Equity shares
21 Sep 2022 2.0 Final 22 Sep 2022 Equity shares
23 May 2022 2.0 Interim 24 May 2022 Equity shares
20 Sep 2021 1.5 Final 21 Sep 2021 Equity shares
18 May 2021 1.5 Interim 19 May 2021 Equity shares
21 Sep 2020 0.4 Final 23 Sep 2020 Equity shares
12 Mar 2020 2.1 Interim 13 Mar 2020 Equity shares
04 Sep 2019 2.2 Final 06 Sep 2019 Equity shares
18 Sep 2018 2.0 Final 20 Sep 2018 Equity shares
07 Sep 2017 1.5 Final 09 Sep 2017 Equity shares
01 Sep 2016 3.5 Final 03 Sep 2016 Equity shares
15 Feb 2016 2.5 Interim 16 Feb 2016 Equity shares
29 Oct 2015 5.0 Final 31 Oct 2015 Equity shares
11 Dec 2014 4.0 Final 13 Dec 2014 Equity shares
19 Dec 2013 2.5 Final 21 Dec 2013 Equity shares
11 Dec 2012 2.0 Final 13 Dec 2012 Equity shares
12 Dec 2011 1.5 Final 24 Dec 2011 Equity shares
09 Dec 2010 1.0 Final 22 Dec 2010 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
19 Oct 2016 10.0 2.0 20 Oct 2016

CAPLIN POINT LAB LTD. Share Price

Promoted by Mr. C. C. Paarthipan, Caplin Point Laboratories Limited was incorporated on April 16th, 1990. The Company is a fully integrated Pharma Company and is presently into the business of pharmaceuticals like producing, developing and marketing wide range of generic formulations and branded products and exporting to overseas market. Its main research and development facilities are located in Tamil Nadu, India and has a manufacturing plant in Puducherry, India. It has over 4000+ products registrations across the globe with over 650+ pharmaceutical formulations & over 36 therapeutic sections.

Caplin markets a wide spectrum of pharmaceutical formulations and therapeutic segments in 23 countries. In addition to LATAM and Africa, it is now serving the US, European Union and other regulated markets as well. It manufactures products one among which is for injectables approved inter-alia by EU-GMP, INVIMA, Colombia, Anvisa, Brazil and US FDA. Besides these, it has extended to regulated markets like USA (plans for Canada, Australia, China and Brazil).

The company came out with a public issue in Nov.'94 and expanded its production capacity by setting up a new unit to manufacture its range of products, at Pondicherry. The company has retained its SSI status even after the expansion and thus will be out of the purview of the DPCO. During 1993-94, Triwin (a partnership firm) was merged with Caplin Point.

The company entered into a technical agreement with American Remedies and Concord Laboratories, US, for specific products, with a 30% buyback arrangement. It also imports bio-technological products to market them in India.

The company has established a trading branch in Nairobi, Kenya, to sell its products in East Africa. It has also established a warehouse in Miami, US, by entering into a marketing tie-up with Lockett Medical Corporation, US.During the year 2015, the Company has invested a sum of Rs 89.10 Lakhs in Argus Salud Pharma LLP. Consequently the Company's share in LLP has increased to 99.90% in Argus Salud Pharma LLP.In October 2016, the Company had subdivided the shares from the face value of Rs 10/- to Rs 2/- and upon sub-division, the members were issued five equity shares of Rs 2/- each in lieu of one equity share of Rs 10/- each. After sub-division, the paid up capital of Rs15,11,00,000 was sub- divided into 7,55,50,000 equity shares of Rs 2/- each.As on 31 March 2018, the Company has three subsidiaries, viz Argus Salud Pharma LLP, Caplin Point Far East Limited - Hongkong and Caplin Point Laboratories Colombia SAS- Colombia.

During the year 2019, the Company transferred its regulated markets injectable business which, inter-alia includes US FDA approved injectable plant and Department of Science and Industrial Research (DSIR) recognised R& D Units CP4 and CP 5 to Caplin Steriles Limited, a Wholly Owned Subsidiary Company for which the approval was granted by the members of the Company by way of Special Resolution through Postal Ballot on December 31, 2018.

In FY2019, the Company attracted investments in Caplin Steriles Limited from Eight Roads Ventures India Ill LP and F-Prime Capital Partners Life Sciences Fund VI LP in the form of Compulsorily Convertible Preference Shares (CCPS), which shall be converted into equity shares of Caplin Steriles Limited based on the agreed terms.

During FY 2019, the Company formed a Joint Venture, Hainan Jointown Caplinpoint Pharmaceutical Company Limited in Hainan Province of China, which will be focusing on international trade of medicines and establishment of marketing team in India and China for export of composite formulations to customers in China, India, Europe and Latin America.

In FY'21, Company acquired four channel partners in Latin America, strengthening control on marketing, distribution and supply chain. It launched an e-commerce website named QueTenX', a part of the 10X healthcare portal, transforming credit sales into cash, enhancing an analysis of demand and supply patterns and replenishment stocks through technology tools. It deepened capabilities by stocking essential products at warehouses during the COVID-19 months. It commissioned a DGCI-approved CRO facility and captive API development kilo lab to facilitate backward integration. It received approvals for nine of 18 ANDAs filed (six for Caplin Steriles); five products launched; the next four to be launched in the near future. It embarked on a pipeline of 15 ANDAs to be filed within 24 months with an addressable market size of USD 1.95 billion. It completed ab scale batches for 17 products for US (by Caplin's API division) and trebled capacity of the manufacturing facility.

The Company received four ANDA approvals since January 2021, increasing approved ANDAs to 15 (ten under Caplin's name and five through partners). It launched eight products in US; four products are ready for launch and three are likely to be launched before December 2021. It received large tender orders worth $18 million in two markets and has started R&D for API and Oncology formulations in existing and new markets. The registrations for formulations are in progress as such. The design /detailed engineering for Phase 2 of Injectable Plant is complete. Overall Project cost is Rs. 140 Crore and will include 2 Vial lines, one Lyophilizer line, one Pre- filled syringe line and provision to add another Pre-mix bag line.

During the year 2022-23, the Company had disposed its entire investment in Caplin Point Laboratories Colombia SAS to Caplin Point Far East Limited - Hong Kong, a wholly - owned subsidiary of the Company and effective from March 28, 2023, Caplin Point Laboratories Colombia SAS ceased to be a subsidiary but became a step-down subsidiary.

In 2023, Caplin doubled its capacity to produce Softgel formulation at its Puducherry facility. The Company implemented the latest, S4 hana, version of SAP - enterprise resource planning system. It developed new line of products i.e. Oncology. It completed 4 complex products Exhibit Batches, which includes 3 Injectables and 1 Ophthalmic; launched co-labelled products in the US, for 4 approved products. It launched 23 new products in Central America which has contributed to $2.4m dollars in sale. The second line of production in Softgel dosage was completed in 2023. It acquired an API plant in Visakhapatnam, Andhra Pradesh.

Parent organization Indian Private
NSE symbol CAPLIPOINT
Founded 1990
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Caplin Point Laboratories Ltd?

Answer Field

The share price of Caplin Point Laboratories Ltd for NSE is ₹ 1806.7 and for BSE is ₹ 1819.55.

What is the Market Cap of Caplin Point Laboratories Ltd?

Answer Field

The market cap of Caplin Point Laboratories Ltd for NSE is ₹ 1,37,20.39 Cr. and for BSE is ₹ 1,38,17.98 Cr. as of now.

What is the 52 Week High and Low of Caplin Point Laboratories Ltd?

Answer Field

The 52 Week High and Low of Caplin Point Laboratories Ltd for NSE is ₹ 2641.00 and ₹ 1225.00 and for BSE is ₹ 2636.00 and ₹ 1221.00.

How to Buy Caplin Point Laboratories Ltd share?

Answer Field

You can trade in Caplin Point Laboratories Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Caplin Point Laboratories Ltd?

Answer Field

The 1 year returns on the stock has been 41.04%.

What is the Current Share Price of Caplin Point Laboratories Ltd?

Answer Field

Caplin Point Laboratories Ltd share price is for NSE ₹ 1806.7 & for BSE ₹ 1819.55 as on Apr 25 2025 03:30 PM.

What is the Market Cap of Caplin Point Laboratories Ltd Share?

Answer Field

The market cap of Caplin Point Laboratories Ltd for NSE ₹ 1,37,20.39 & for BSE ₹ 1,38,17.98 as on Apr 25 2025 03:30 PM.

What is the P/E Ratio of Caplin Point Laboratories Ltd Share?

Answer Field

As on Apr 25 2025 03:30 PM the price-to-earnings (PE) ratio for Caplin Point Laboratories Ltd share is 44.38.

What is the PB ratio of Caplin Point Laboratories Ltd Share?

Answer Field

As on Apr 25 2025 03:30 PM, the price-to-book (PB) ratio for Caplin Point Laboratories Ltd share is 201.93.

How to Buy Caplin Point Laboratories Ltd Share?

Answer Field

You can trade in Caplin Point Laboratories Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Caplin Point Laboratories Ltd Share on Bajaj Broking App?

Answer Field

To buy Caplin Point Laboratories Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Caplin Point Laboratories Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|